In conclusion, this study provides the first preclinical evidence that HMC, particularly in combination with MTX, ameliorates IMQ-induced psoriasis via modulation of inflammatory cytokines, oxidative stress, and histopathological damage. These findings suggest its potential as a therapeutic candidate that warrants further preclinical and clinical investigation in plaque-type psoriasis.

Despite 3 years of acitretin therapy, surgical excisions, imiquimod and repeated cryotherapy, the lesions remained poorly controlled. This case, along with her sister's experience, highlights oral methotrexate as a potential therapeutic option for refractory cases. Further studies are needed to explore its role in the management of this challenging condition.

A course of unlicensed therapeutic human papillomavirus vaccination and topical imiquimod for 6 months was attempted, without benefit...PDL remains unlicensed in the UK for treatment of warts and is not widely available. We report this case with the objective of highlighting (i) the potential value of this treatment for refractory warts in immunocompromised individuals and (ii) the need for clinical trials to assess its efficacy in immunocompromised cohorts.

This study demonstrates that Huai'er (Trametes) exerts therapeutic effects on psoriasis by modulating STAT1, thereby inhibiting keratinocyte proliferation and inflammatory responses. The findings provide a foundation for further research into the potential of Huai'er (Trametes) as a treatment for psoriasis.

In plasma, IL-22 was elevated in IMQ-treated animals but decreased in the IMQ + LED group (p < 0.05), while no significant changes were detected for IL-1β, IL-17A, IL-23, TNF-α, or macrophage inflammatory protein (MIP)-3α. Together, these results suggest that red LED phototherapy reduces clinical severity and partially modulates both local and systemic inflammation in IMQ-induced psoriasis, supporting its potential as a complementary therapeutic approach.

The 6-week IMQ-applied IL-10 KO model may better reflect chronic and severe psoriasis with gut-related comorbidities, offering a valuable platform to investigate the gut-skin axis.

A standard drug group receiving methotrexate (MTX) was included to benchmark the efficacy of aloesin. MTX, as a standard comparator, allowed for direct benchmarking of aloesin anti-psoriatic effects. Psoriasis treatment could benefit from this approach in the future.

To overcome these barriers, a pH-responsive solid lipid nanoparticle (SLN) system was engineered to co-deliver CB-5083 (a VCP/p97 inhibitor), miR-142 (a PD-L1-targeting microRNA), and imiquimod (R, a TLR7 agonist) for spatially confined induction of endoplasmic reticulum stress (ERS) and immune reprogramming in MSS CRC. Biodistribution analysis confirmed tumor-preferential accumulation with minimal off-target exposure, and biosafety profiling demonstrated low systemic toxicity. This TME-responsive nanoplatform therefore integrates ERS induction, checkpoint modulation, and cytokine suppression to overcome immune exclusion in MSS CRC, representing a clinically translatable strategy for chemo-immunotherapy in immune-refractory tumors.

P1/2, N=18, Recruiting, Instituto Oncológico Dr Rosell

Anti IL-2/IL-2 complex therapy effectively ameliorated the clinical manifestations of psoriasis, with no apparent side effects, providing a new strategy for treating psoriasis.

P2, N=20, Recruiting, Melanoma Institute Australia | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026

Topical imiquimod successfully cured the lesion only after abatacept discontinuation in the patient. Our case suggests that abatacept has depleted the production of tumor necrosis factor-α by macrophages upon contact with imiquimod, which is a toll-like receptor 7 ligand.